PIK3CA and non-small cell lung carcinoma: Six studies evaluated the expression of the PI3K/AKT/mTOR pathway in breast cancer, five in gastrointestinal tumors, three in gynecological cancers, and one each in prostate, non-small cell lung cancer (NSCLC) and oropharyngeal cancers.